Notably, the inhibition of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) became the first successful checkpoint blockade in cancer immunotherapy, highlighting the critical role of costimulatory signaling in T-cell activation [2]. Here, CTLA4 is linked to cancer.